Skip to main content
Loading
Matthew Spear

Matthew Spear

Chief Development Officer and Chief Medical Officer, Denovo Biopharma
Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from the Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications.